Actelion Ltd (ATLN) - Financial and Strategic SWOT Analysis Review

June 2017 | 56 pages | ID: AFCD3008A91EN
GlobalData

Abstracts

Actelion Ltd (ATLN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Actelion Ltd (Actelion) is a biopharmaceutical company, which strives to discover, develop and commercialize innovative treatments for diseases with considerable unmet medical needs. The company focuses on the development of treatments for pulmonary arterial hypertension (PAH). Its PAH franchise products include endothelin receptor antagonists (ERAs) Tracleer (bosentan), Opsumit (macitentan), Veletri (epoprostenol for injection), Ventavis (iloprost) and Uptravi (selexipag). Its specialty products include Valchlor (mechlorethamine), Ledaga (chlormethine) and Zavesca (miglustat). Actelion also offers approved treatments for diseases such as Type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients with systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. The company offers its products in various countries across Europe, besides Japan, China, Russia, Mexico and the US. Actelion is headquartered in Allschwil, Switzerland.

Actelion Ltd Key Recent Developments

May 22,2017: Actelion provides an update on the progress towards launching Idorsia - Key results for pipeline assets to be developed by Idorsia
May 15,2017: Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson
Feb 14,2017: Actelion announces excellent financial results for 2016
Nov 07,2016: Actelion To Provide An Update On Advancements In Its Cardiovascular Pipeline In PAH And Beyond
Oct 20,2016: Excellent Operational Results - Supported By Outstanding Uptravi Launch - Financial Guidance Upgraded

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Actelion Ltd - Key Facts
Actelion Ltd - Key Employees
Actelion Ltd - Key Employee Biographies
Actelion Ltd - Major Products and Services
Actelion Ltd - History
Actelion Ltd - Company Statement
Actelion Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Actelion Ltd - Business Description
Actelion Ltd - SWOT Analysis
SWOT Analysis - Overview
Actelion Ltd - Strengths
Actelion Ltd - Weaknesses
Actelion Ltd - Opportunities
Actelion Ltd - Threats
Actelion Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Actelion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Actelion Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Actelion Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 22, 2017: Actelion provides an update on the progress towards launching Idorsia - Key results for pipeline assets to be developed by Idorsia
May 15, 2017: Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson
Feb 14, 2017: Actelion announces excellent financial results for 2016
Nov 07, 2016: Actelion To Provide An Update On Advancements In Its Cardiovascular Pipeline In PAH And Beyond
Oct 20, 2016: Excellent Operational Results - Supported By Outstanding Uptravi Launch - Financial Guidance Upgraded
Jul 21, 2016: Very Strong Performance in the First Half Of 2016 - Enhanced by Successful Uptravi US Launch
Apr 21, 2016: Very Strong Performance Continues In The First Quarter Of 2016 - Driven By Outcome-Based Pah Portfolio

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Actelion Ltd, Key Facts
Actelion Ltd, Key Employees
Actelion Ltd, Key Employee Biographies
Actelion Ltd, Major Products and Services
Actelion Ltd, History
Actelion Ltd, Subsidiaries
Actelion Ltd, Joint Venture
Actelion Ltd, Key Competitors
Actelion Ltd, Ratios based on current share price
Actelion Ltd, Annual Ratios
Actelion Ltd, Annual Ratios (Cont.1)
Actelion Ltd, Annual Ratios (Cont.2)
Actelion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Actelion Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Actelion Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Actelion Ltd, Performance Chart (2012 - 2016)
Actelion Ltd, Ratio Charts
Actelion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Actelion Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Santhera Pharmaceuticals Holding AG
Mymetics Corp
Merck Serono SA
F. Hoffmann-La Roche Ltd
Anavex Life Sciences Corp
Alpex Pharma SA